Debora Melo van Lent1,2, Sarah Egert3, Steffen Wolfsgruber1,4, Luca Kleineidam4, Leonie Weinhold5, Holger Wagner-Thelen4, Wolfgang Maier4, Frank Jessen1,6, Alfredo Ramirez1,6,7, Matthias Schmid1,5, Martin Scherer8, Steffi G Riedel-Heller9, Michael Wagner1,4. 1. German Center for Neurodegenerative Diseases (DZNE), 53127 Bonn, Germany. 2. Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio, TX 78229, USA. 3. Institute of Nutritional Medicine, University of Hohenheim, 70599 Stuttgart, Germany. 4. Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, 53127 Bonn, Germany. 5. Department of Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, 53105 Bonn, Germany. 6. Department of Psychiatry, Medical Faculty, University of Cologne, 50924 Cologne, Germany. 7. Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, University of Cologne, Medical Faculty, 50937 Cologne, Germany. 8. Department of Primary Medical Care, Center for Psychosocial Medicine, University Medical Center, Hamburg-Eppendorf, 20146 Hamburg, Germany. 9. Institute of Social Medicine, Occupational Health and Public Health, University of Leipzig, 04103 Leipzig, Germany.
Abstract
BACKGROUND: Omega-3 (n-3) and omega-6 (n-6) polyunsaturated fatty acids (PUFAs) may have different effects on cognitive health due to their anti- or pro-inflammatory properties. METHODS: We aimed to prospectively examine the relationships between n-3 and n-6 PUFA contents in serum phospholipids with incident all-cause dementia and Alzheimer's disease dementia (AD). We included 1264 non-demented participants aged 84 ± 3 years from the German Study on Ageing, Cognition, and Dementia in Primary Care Patients (AgeCoDe) multicenter-cohort study. We investigated whether fatty acid concentrations in serum phospholipids, especially eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), alpha-linolenic acid (ALA), linoleic acid (LA), dihomo-γ-linolenic acid (DGLA), and arachidonic acid (AA), were associated with risk of incident all-cause dementia and AD. RESULTS: During the follow-up window of seven years, 233 participants developed dementia. Higher concentrations of EPA were associated with a lower incidence of AD (hazard ratio (HR) 0.76 (95% CI 0.63; 0.93)). We also observed that higher concentrations of EPA were associated with a decreased risk for all-cause dementia (HR 0.76 (95% CI 0.61; 0.94)) and AD (HR 0.66 (95% CI 0.51; 0.85)) among apolipoprotein E ε4 (APOE ε4) non-carriers but not among APOE ε4 carriers. No other fatty acids were significantly associated with AD or dementia. CONCLUSIONS: Higher concentrations of EPA were associated with a lower risk of incident AD. This further supports a beneficial role of n-3 PUFAs for cognitive health in old age.
BACKGROUND:Omega-3 (n-3) and omega-6 (n-6) polyunsaturated fatty acids (PUFAs) may have different effects on cognitive health due to their anti- or pro-inflammatory properties. METHODS: We aimed to prospectively examine the relationships between n-3 and n-6 PUFA contents in serum phospholipids with incident all-cause dementia and Alzheimer's diseasedementia (AD). We included 1264 non-demented participants aged 84 ± 3 years from the German Study on Ageing, Cognition, and Dementia in Primary Care Patients (AgeCoDe) multicenter-cohort study. We investigated whether fatty acid concentrations in serum phospholipids, especially eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), alpha-linolenic acid (ALA), linoleic acid (LA), dihomo-γ-linolenic acid (DGLA), and arachidonic acid (AA), were associated with risk of incident all-cause dementia and AD. RESULTS: During the follow-up window of seven years, 233 participants developed dementia. Higher concentrations of EPA were associated with a lower incidence of AD (hazard ratio (HR) 0.76 (95% CI 0.63; 0.93)). We also observed that higher concentrations of EPA were associated with a decreased risk for all-cause dementia (HR 0.76 (95% CI 0.61; 0.94)) and AD (HR 0.66 (95% CI 0.51; 0.85)) among apolipoprotein E ε4 (APOE ε4) non-carriers but not among APOE ε4 carriers. No other fatty acids were significantly associated with AD or dementia. CONCLUSIONS: Higher concentrations of EPA were associated with a lower risk of incident AD. This further supports a beneficial role of n-3 PUFAs for cognitive health in old age.
Authors: Karin Yurko-Mauro; Deanna McCarthy; Dror Rom; Edward B Nelson; Alan S Ryan; Andrew Blackwell; Norman Salem; Mary Stedman Journal: Alzheimers Dement Date: 2010-11 Impact factor: 21.566
Authors: Martha Clare Morris; Denis A Evans; Julia L Bienias; Christine C Tangney; David A Bennett; Neelum Aggarwal; Julie Schneider; Robert S Wilson Journal: Arch Neurol Date: 2003-02
Authors: Catherine M Milte; Natalie Sinn; Steven J Street; Jonathan D Buckley; Alison M Coates; Peter R C Howe Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2011-03-09 Impact factor: 4.006
Authors: Jonathan A C Sterne; Ian R White; John B Carlin; Michael Spratt; Patrick Royston; Michael G Kenward; Angela M Wood; James R Carpenter Journal: BMJ Date: 2009-06-29
Authors: Tobias Luck; Steffi G Riedel-Heller; Hanna Kaduszkiewicz; Horst Bickel; Frank Jessen; Michael Pentzek; Birgitt Wiese; Heike Koelsch; Hendrik van den Bussche; Heinz-Harald Abholz; Edelgard Moesch; Sandra Gorfer; Matthias C Angermeyer; Wolfgang Maier; Siegfried Weyerer Journal: Dement Geriatr Cogn Disord Date: 2007-09-11 Impact factor: 2.959
Authors: Aleix Sala-Vila; Claudia L Satizabal; Nathan Tintle; Debora Melo van Lent; Ramachandran S Vasan; Alexa S Beiser; Sudha Seshadri; William S Harris Journal: Nutrients Date: 2022-06-09 Impact factor: 6.706